211 related articles for article (PubMed ID: 35488348)
1. Autologous hematopoietic stem cell transplantation promotes connective tissue remodeling in systemic sclerosis patients.
Zanin-Silva DC; Santana-Gonçalves M; Kawashima-Vasconcelos MY; Lima-Júnior JR; Dias JBE; Moraes DA; Covas DT; Malmegrim KCR; Ramalho L; Oliveira MC
Arthritis Res Ther; 2022 Apr; 24(1):95. PubMed ID: 35488348
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis.
Zhang BB; Cai WM; Weng HL; Hu ZR; Lu J; Zheng M; Liu RH
World J Gastroenterol; 2003 Nov; 9(11):2490-6. PubMed ID: 14606082
[TBL] [Abstract][Full Text] [Related]
3. Changes of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) after autologous hematopoietic stem cell transplantation in multiple sclerosis.
Blanco Y; Saiz A; Carreras E; Graus F
J Neuroimmunol; 2004 Aug; 153(1-2):190-4. PubMed ID: 15265677
[TBL] [Abstract][Full Text] [Related]
4. Matrix Metalloproteinases MMP-2 and MMP-9, Their Inhibitors TIMP-1 and TIMP-2, Vascular Endothelial Growth Factor and sVEGFR-2 as Predictive Markers of Ischemic Retinopathy in Patients with Systemic Sclerosis-Case Series Report.
Waszczykowska A; Podgórski M; Waszczykowski M; Gerlicz-Kowalczuk Z; Jurowski P
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218057
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive Therapy After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients-High Efficacy of Rituximab.
Gernert M; Tony HP; Fröhlich M; Schwaneck EC; Schmalzing M
Front Immunol; 2021; 12():817893. PubMed ID: 35111167
[TBL] [Abstract][Full Text] [Related]
6. Non-Classical HLA Determinants of the Clinical Response after Autologous Stem Cell Transplantation for Systemic Sclerosis.
Boukouaci W; Lansiaux P; Lambert NC; Picard C; Clave E; Cras A; Marjanovic Z; Farge D; Tamouza R
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806227
[TBL] [Abstract][Full Text] [Related]
7. Decreased MMP-9 activity in the serum of patients with diffuse cutaneous systemic sclerosis.
Kikuchi K; Kubo M; Hoashi T; Tamaki K
Clin Exp Dermatol; 2002 Jun; 27(4):301-5. PubMed ID: 12139676
[TBL] [Abstract][Full Text] [Related]
8. Elevated matrix metalloproteinase-9 in patients with systemic sclerosis.
Kim WU; Min SY; Cho ML; Hong KH; Shin YJ; Park SH; Cho CS
Arthritis Res Ther; 2005; 7(1):R71-9. PubMed ID: 15642145
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis.
Yazawa N; Kikuchi K; Ihn H; Fujimoto M; Kubo M; Tamaki T; Tamaki K
J Am Acad Dermatol; 2000 Jan; 42(1 Pt 1):70-5. PubMed ID: 10607322
[TBL] [Abstract][Full Text] [Related]
10. Plasma Glycosaminoglycan Profiles in Systemic Sclerosis: Associations with MMP-3, MMP-10, TIMP-1, TIMP-2, and TGF-Beta.
Kuźnik-Trocha K; Winsz-Szczotka K; Komosińska-Vassev K; Jura-Półtorak A; Kotulska-Kucharz A; Kucharz EJ; Kotyla P; Olczyk K
Biomed Res Int; 2020; 2020():6416514. PubMed ID: 32382564
[TBL] [Abstract][Full Text] [Related]
11. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE
Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
[TBL] [Abstract][Full Text] [Related]
12. The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity.
Toubi E; Kessel A; Grushko G; Sabo E; Rozenbaum M; Rosner I
Clin Exp Rheumatol; 2002; 20(2):221-4. PubMed ID: 12051403
[TBL] [Abstract][Full Text] [Related]
13. Autologous hematopoietic stem cell transplantation modifies specific aspects of systemic sclerosis-related microvasculopathy.
Santana-Gonçalves M; Zanin-Silva D; Henrique-Neto Á; Moraes DA; Kawashima-Vasconcelos MY; Lima-Júnior JR; Dias JBE; Bragagnollo V; de Azevedo JTC; Covas DT; Malmegrim KCR; Ramalho L; Oliveira MC
Ther Adv Musculoskelet Dis; 2022; 14():1759720X221084845. PubMed ID: 35368373
[TBL] [Abstract][Full Text] [Related]
14. Antifibrotic effects of crocetin in scleroderma fibroblasts and in bleomycin-induced sclerotic mice.
Song Y; Zhu L; Li M
Clinics (Sao Paulo); 2013 Oct; 68(10):1350-7. PubMed ID: 24212843
[TBL] [Abstract][Full Text] [Related]
15. Relationship between matrix metalloproteinases/tissue inhibitors of matrix metalloproteinases systems and autoantibody patterns in systemic sclerosis.
Montagnana M; Volpe A; Lippi G; Caramaschi P; Salvagno GL; Biasi D; Bambara LM; Guidi GC
Clin Biochem; 2007 Aug; 40(12):837-42. PubMed ID: 17493602
[TBL] [Abstract][Full Text] [Related]
16. Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage.
Manetti M; Guiducci S; Romano E; Bellando-Randone S; Conforti ML; Ibba-Manneschi L; Matucci-Cerinic M
Ann Rheum Dis; 2012 Jun; 71(6):1064-72. PubMed ID: 22258486
[TBL] [Abstract][Full Text] [Related]
17. [Effects of Wenyang Huazhuo Tongluo Recipe Containing Serum on Transforming Growth Factor β1/ Smad Signaling Pathway of Skin Fibroblasts in Systemic Sclerosis].
Bian H; Lv Q; Huang XZ; Hu JL; Yang L; Mao BY
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Sep; 35(9):1054-9. PubMed ID: 26591358
[TBL] [Abstract][Full Text] [Related]
18. Homeostatic proliferation leads to telomere attrition and increased PD-1 expression after autologous hematopoietic SCT for systemic sclerosis.
Arruda LCM; Lima-Júnior JR; Clave E; Moraes DA; Douay C; Fournier I; Moins-Teisserenc H; Covas DT; Simões BP; Farge D; Toubert A; Malmegrim KCR; Oliveira MC
Bone Marrow Transplant; 2018 Oct; 53(10):1319-1327. PubMed ID: 29670207
[TBL] [Abstract][Full Text] [Related]
19. Supernatants from culture of type I collagen-stimulated PBMC from patients with cutaneous systemic sclerosis versus localized scleroderma demonstrate suppression of MMP-1 by fibroblasts.
Brown M; Postlethwaite AE; Myers LK; Hasty KA
Clin Rheumatol; 2012 Jun; 31(6):973-81. PubMed ID: 22367096
[TBL] [Abstract][Full Text] [Related]
20. Outcomes in progressive systemic sclerosis treated with autologous hematopoietic stem cell transplantation compared with combination therapy.
Keret S; Henig I; Zuckerman T; Kaly L; Shouval A; Awisat A; Rosner I; Rozenbaum M; Boulman N; Dortort Lazar A; Molad Y; Sabbah F; Naffaa ME; Hardak E; Slobodin G; Rimar D
Rheumatology (Oxford); 2024 May; 63(6):1534-1538. PubMed ID: 37672021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
